A Research Registry on Aggressive PitNETs
ConditionEndocrine Tumor
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHospices Civils de Lyon
About this trial
To allow the identification of markers, it is necessary to extend research networks more widely to collect and properly explore aggressive pituitary tumours. The multidisciplinary consultation meeting (RCP), organised by the reference centre for rare diseases of the pituitary gland, dedicated to aggressive pituitary tumours and carcinomas (HYPOcare), which is unique in France and brings together national experts, currently makes it possible to orientate the management of patients with an aggressive pituitary tumour. With more than 80 patient files discussed since its inception, the patient cohort via the HYPOcare RCP is one of the largest both nationally and internationally. At present, this data source is only dedicated to the clinical management of the files without the possibility of carrying out research work
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with a diagnosis of pituitary tumour
Patients whose file has been presented to the national HYPOcare RCP
Disqualifiers
Patients objecting to participating in this research
Trial population
Adult subjects with pituitary tumours whose file is presented to the national HYPOcare RCP. There is only one group.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
200 Participants
are grouped into 1 trial groupGroup A: Patients RECAPitNETT
Trial outcomes
Primary outcomes
1
Characterisation of aggressiveness of pituitary tumours by tanscriptome analysis
Molecular and transcriptomic signature of aggressiveness of pituitary tumours predictive of prognosis
Time frame
3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov